Table 1.
Summary of breast cancer-associated lncRNAs.
| LncRNAs | Expression status | Oncogene/tumor suppressor | Cell processes | Clinical outcomes | References |
|---|---|---|---|---|---|
| MALAT1 | Upregulated | Oncogene | Proliferation, invasion, migration, recurrence, drug resistance and angiogenesis | Unfavorable OS, DFS and RFS | (32–47) |
| NEAT1 | Upregulated | Oncogene | Proliferation, invasion and metastasis | Tumor volume, lymph node metastasis and poor prognosis | (48–56) |
| H19 | Upregulated | Oncogene | Proliferation, metastasis, invasion | Shorter OS and DFS | (57–64) |
| AFAP1-AS1 | Upregulated | Oncogene | Proliferation, anti-apoptosis, migration and invasion | Greater tumor volume, advanced TNM stage, lymph node metastasis and distant metastasis | (65–72) |
| HOTAIR | Upregulated | Oncogene | Proliferation, anti-apoptosis, migration and invasion | Advanced tumor stage, enhanced metastasis and unfavorable prognosis | (73–79) |
| ROR | Upregulated | Oncogene | Cell growth, migration, invasiveness and drug resistance | Poor prognosis | (80–85) |
| ANRIL | Upregulated | Oncogene | Proliferation | Increased tumor size, advanced TNM stage and unfavorable prognosis | (86–91) |
| BC200 | Upregulated | Oncogene | Proliferation, migration and invasion | Poor prognosis | (92–95) |
| SPRY4-IT1 | Upregulated | Oncogene | Proliferation, invasion and metastasis | Increased tumor size, high TNM stage, lymph node metastasis and unfavorable prognosis | (96–99) |
| UCA1 | Upregulated | Oncogene | Proliferation, invasion and metastasis | Increased lymph node metastasis and shorter OS | (100–104) |
| ATB | Upregulated | Oncogene | Drug resistance, anti-apoptosis, proliferation, invasion and metastasis | More nodal metastasis, advanced clinical stage and unfavorable prognosis | (105–109) |
| PVT1 | Upregulated | Oncogene | Proliferation, invasion and migration | More lymph node metastasis, increased distant metastasis, advanced TNM stage, poor differentiation grade and unfavorable prognosis | (110–115) |
| CCAT1 | Upregulated | Oncogene | Radio resistance, proliferation, invasion and metastasis | Histological grade, TNM staging and lymph metastasis, and poor prognosis | (116–119) |
| CCAT2 | Upregulated | Oncogene | Proliferation, invasion and metastasis | Greater tumor volume, higher TNM grades, advanced clinical stage and a poor OS | (120–124) |
| TINCR | Upregulated | Oncogene | Proliferation, anti-apoptosis, migration and invasion | unfavorable prognosis | (125–128) |
| MEG3 | Downregulated | Tumor suppressor | Proliferation, anti-apoptosis, metastasis and invasion | Advanced TNM stage, lymph node metastasis and differentiation grade | (129–137) |
| XIST | Downregulated | Tumor suppressor | Proliferation, migration, invasion and anti-apoptosis | Larger tumor volume, increased lymphatic metastasis, advanced tumor stage and unfavorable prognosis | (138–144) |
| PTENP1 | Downregulated | Tumor suppressor | Proliferation, colony formation, migration, invasion and anti-apoptosis | Advanced TNM stage and worse OS | (145–149) |